Future scope: 2026-2035.
This page is an iFeed horizon scan, not a regulatory roadmap. It separates official source direction from iFeed forecast so future-facing signals do not read as confirmed obligations before regulators publish them.
Future scope: 2026-2035.
What's coming · with confidence indicatorsThis page is an iFeed horizon scan, not a regulatory roadmap. Confidence is high only where official source direction is visible, medium where industry practice is moving ahead of formal text, and watch where the signal is still an iFeed forecast.
ICH M10 revision horizon.
Any future revision of ICH M10 would be highly material for bioanalytical practice. Until an official ICH timetable is linked, iFeed treats specific dates as forecast, not confirmed regulatory schedule.Watch
Acceptance logic retained.
The ±15% / ±20% LLOQ logic and run/QC acceptance culture are deeply embedded in current guidance and practice. iFeed does not see a near-term signal that this core will disappear.High
Tiered validation matures.
Biomarker validation will keep moving toward clearer context-of-use and fit-for-purpose documentation. Public wording should avoid saying formalisation is guaranteed unless tied to a named official text.Medium
Use cases expand.
Surrogate-matrix questions are likely to grow around endogenous compounds and advanced modalities. Candidate examples should be treated as iFeed horizon examples, not a regulatory list.
Evidence framing tightens.
For biomarkers and advanced modalities, teams should expect stronger scrutiny of intended use, decision context, and whether validation is proportionate to the role of the measurement.Medium
Boundary watch.
Companion diagnostics, IVDR, and bioanalytical PK/PD evidence remain adjacent but distinct regulatory worlds. iFeed will track convergence signals without presenting them as merged obligations.
VCN and potency-adjacent assays.
Vector-copy-number and other cell/gene-therapy assays are likely to keep pressure on classical BMV language. Current public claims should be framed as advanced-modality watch items unless source-linked.
Anti-vector evidence.
Anti-vector immune response work should be handled through immunogenicity and context-of-use evidence language. Avoid implying a single harmonised path where regulators remain case-specific.
HRMS as additive capability.
High-resolution MS is an important capability, but public pages should describe adoption as a technology trend rather than universal regulatory acceptance by a fixed year.
Triple-quad workhorse.
Installed base massive. CRO infrastructure QQQ-centric. HRMS additive, not replacing.High
Reagent-lot bridging.
Reagent-lot bridging may become more prominent as ISR processes mature and biologic/advanced-modality methods rely on critical reagents. Treat as an evidence-readiness watch item unless dataset-backed.
Combination-product interfaces.
QMSR raises the importance of device design-control evidence. iFeed will track whether that creates clearer bridges between DHF/design records and bioanalytical evidence for combination-product programmes.
Forecast boundary: This page uses official sources as anchors and labels forward-looking statements as iFeed horizon interpretation. It should not be read as legal advice, regulatory prediction, or a confirmed ICH/FDA/EMA/PMDA/ANVISA timetable.
Source register.
official anchors · interpretation kept separateThis bioanalytical page uses official guidance as the source layer and separates iFeed interpretation from regulator text. Jurisdiction-specific details should be checked against the current regulator page before use in submissions, audits, or public checklists.
ICH M10 EU page.
EMA ICH M10 scientific guideline. Earlier EMA BMV guidance should be marked as historical where used for comparison.